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Abstract There is an increasing amount of data indicating
that primary hypertension (PH) is not only a hemodynamic
phenomenon but also a complex syndrome involving abnor-
mal fat tissue distribution, over-activity of the sympathetic
nervous system (SNS), metabolic abnormalities, and activa-
tion of the immune system. In children, PH usually presents
with a typical phenotype of disturbed body composition, ac-
celerated biological maturity, and subtle immunological and
metabolic abnormalities. This stage of the disease is potential-
ly reversible. However, long-lasting over-activity of the SNS
and immuno-metabolic alterations usually lead to an irrevers-
ible stage of cardiovascular disease. We describe an interme-
diate phenotype of children with PH, showing that PH is as-
sociated with accelerated development, i.e., early premature
aging of the immune, metabolic, and vascular systems. The
associations and determinants of hypertensive organ damage,
the principles of treatment, and the possibility of rejuvenation
of the cardiovascular system are discussed.
Keywords Primary hypertension . Children . Immunologic
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Introduction
In the 1940s, Irvin Page developed his mosaic theory of the
pathogenesis of primary hypertension (PH). The basis of this
concept relied on the recognition of many interconnected fac-
tors, including all known mechanisms playing a role in the
elevation of blood pressure (BP) [1]. The so-called BPage’s
Mosaic^ described an interplay between anatomic, genetic,
metabolic, nervous, hemodynamic, and environmental fac-
tors. The elevation of BP and the eventual development of
PH were the end result of the interplay of all these factors,
indicating that the pathogenesis of PH is multifactorial. De-
spite the fact that many newmechanisms and factors influenc-
ing BP control have been discovered since then, the mosaic
theory is still valid [2].
Another theory was described over 40 years ago by Arthur
Guyton. His model of BP regulation is based on the relation-
ship between volume and peripheral vascular resistance. It
explains the main mechanisms in regulating peripheral blood
flow, along with adaptations of other neural, hormonal, and
autacoid systems concerning the changes in resistance–vol-
ume relations. Moreover, it describes not only physiological
regulations of BP and peripheral flow but also explains the
pathogenesis of most of the secondary forms of arterial hyper-
tension. The main mechanisms of BP control described by
Guyton also work for PH, however both models fail to explain
the inciting events in PH. Recent findings from experimental
and clinical studies have suggested that metabolic abnormal-
ities, sympathetic nervous system (SNS) alterations, immune
activation, early arterial changes and their interrelationships
may in fact represent inciting events in the development of
sustained PH.
Children with PH in the early stages of hypertensive dis-
ease are usually not affected by other confounding factors
typically present in adulthood; issues such as diabetes
mellitus, nicotinism, and atherosclerosis. Thus, data from
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pediatric studies may shed more light on the pathogenesis of
early stages of PH.
Intermediate phenotype of PH in childhood
Anthropometrical and metabolic abnormalities
The relationship between body mass index (BMI) and BP
explains why an increasing prevalence of obesity is associated
with an increased prevalence of PH among children and ado-
lescents [3, 4]. It was reported a decade ago that a typical
phenotype in a child in New York with PH was obesity [5].
The authors also noted that there was a steady increase in the
prevalence of obesity and being overweight by observing an
increasing severity of hypertension from borderline hyperten-
sion to sustained hypertension. This was confirmed by studies
from Europe in hypertensive adolescent subjects who were
taller and heavier than their normotensive peers do [6]. The
association between BMI and the associated metabolic abnor-
malities (such as hyper-insulinism, insulin resistance, IR) and
BP levels is almost linear; such a relationship is observed as
early as 4 years old [7]. Moreover, Sinaiko et al. found that
elevated insulin concentrations and a lower glucose uptake at
the age of 13 preceded the increase of systolic BP at the age of
19 [8]. The data indicate that this is not related to BMI but
rather an increased ratio of visceral fat to subcutaneous fat that
determines metabolic abnormalities and hemodynamic conse-
quences. This phenotype is often accompanied by an in-
creased amount of visceral fat, but a normal or near-normal
BMI and is typical for the metabolic syndrome (MS) [9]. MS
was found in 20 % of hypertensive children in comparison to
only 2 % of the general population [10]. Another typical met-
abolic abnormality in PH is the tendency for hyperuricemia;
hypertensive adolescents tend to have serum uric acid concen-
trations in the upper range of normal values when compared to
normotensive children. Feig et al. showed that elevated serum
uric acid levels differentiated adolescents with PH from those
with white-coat hypertension (WCH) and secondary hyper-
tension, and finally, treatment with allopurinol lowered both
uric acid levels and BP [11–13].
The presence of MS indicates exposure to excessive oxi-
dative stress (SOX) as was shown in a few reports on SOX in
hypertensive children [14–18]. In one of the first pediatric
reports, Goonasekkara et al. reported that hypertensive chil-
dren had significantly increased serum levels of asymmetric
dimethylarginine and symmetric dimethylarginine [15]. In-
creased oxidative stress is typical in obese children when com-
pared with non-obese children [16]. However, hypertensive
children are exposed to greater SOX, irrespective of their
BMI [17]. SOX markers also correlate with 24-h systolic
BP. In a prospective study it was found that hypertensive chil-
dren were exposed to greater SOX, and the SOXmarkers were
significantly associated with left ventricular hypertrophy
(LVH) and the presence of MS [18].
Metabolic abnormalities in PH are not only reversible
but also determine regression of target organ damage
(TOD). In a prospective study of 86 children with PH
who were treated with lifestyle changes and pharmacolog-
ical therapy (based on angiotensin converting enzyme in-
hibitors (ACEi) or angiotensin receptor blockers, ARBs),
blood pressure normalized in 70 % of these patients, while
TOD, SOX, and metabolic and immunological abnormali-
ties significantly regressed. It was found that the only pre-
dictor of a decrease in the left ventricular mass index
(LVMI) and the carotid wall cross-sectional area was a
decrease in visceral obesity expressed by a reduction of
waist circumference (WC) [19].
Accelerated biological maturation
Other findings show that hypertensive adolescents mature
at a slightly faster rate than their normotensive peers. The
idea that PH is a disorder of accelerated growth was ini-
tially introduced by Lever and Harrap in 1992 [20]. They
hypothesized that accelerated biological maturation is as-
sociated with metabolic alterations, including hyper-
insulinism and insulin resistance (IR). Together these alter-
ations may lead to the hypertrophy of arterial wall smooth
muscle cells, along with the development of hypertension
and cardiovascular disease. This hypothesis is supported
by findings of Katz et al. who revealed that the bone age
of hypertensive adolescents was significantly higher when
compared with age-matched groups of normotensive chil-
dren [21]. It was further confirmed by Cho et al., who
found that sexual maturity was an independent predictor
of systolic BP in both boys and girls [22]. In our study,
hypertensive boys had more advanced bone age (on aver-
age by 1.5 years) when compared with normotensive peers.
Moreover, advanced maturation was proportional to the
level of BP; from normotension to pre-hypertension and
furthermore to stage 1 and 2 hypertension [23]. Accelerat-
ed maturation is also linked with BMI and visceral obesity.
A retrospective analysis from the ‘Fels Longitudinal
Study’ indicated that young adults (18–35 years of age),
who matured early had greater BMI, WC and cardiovascu-
lar risk factors than those who matured at a slower rate
[24]. Similarly, a retrospective study from Iceland found
that adult men who had their highest growth velocity be-
tween the ages of 8 and 13, had a 66 % increased risk of
hypertension when compared to men who had low growth
velocity [25]. The cardiovascular risk associated with in-
creased biological maturation is not limited to males. It has
been found that an earlier age at menarche correlates with
higher BP, visceral obesity, and MS in adulthood [26].
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Activation of immune system in pediatric hypertension
Numerous clinical observations and experimental data indi-
cate the role of innate and adaptive immune responses in the
pathogenesis of PH. Although an innate immune system is
non-specifically activated by both metabolic and hemody-
namic factors, the adaptive T-cell-dependent system seems
to be crucial for maintaining hypertension. This was docu-
mented by the transfer of hypertension, with lymph node cells
from hypertensive to normotensive rats [27]. In the 1970s,
Svendsen reported that an intact thymus was necessary for
maintaining elevated BP in hypertension-prone rats and mice
[28]. Importantly, the role of thymus-derived lymphocytes
was not established during the early stages of the disease;
however, in the chronic stage of experimental hypertension,
mice with an intact thymus had more advanced degenerative
changes within the arterial walls of their intra-renal arteries,
when compared to nude mice with an inherited aplasia of the
thymus. This led to the idea that the T-lymphocyte-dependent
immune reaction is directed against antigens derived from a
hemodynamically injured arterial wall [29]. These observa-
tions were further confirmed by experiments with the hyper-
tension-prone NZB (New Zealand Black) strain of mice, in
which the athymic NZB mice did not develop hypertension
[30]. Since these early reports, many other studies have
shown the role of intact and adaptive immune responses
in the pathogenesis of arterial hypertension. It has been
shown that RAG−/− mice that do not have T-lymphocytes,
do not have elevated BP during angiotensin 2 (AT2) infu-
sions. However, the adoptive transfer of T-cells restored
sensitivity to AT2 [31]. It was also found that T-
regulatory cells (T-regs), which limit the extent of the im-
mune response, play a significant role in the pathogenesis
of arterial hypertension within the experimental setting. In
the mouse model of arterial hypertension, an adoptive
transfer of T-regs limited hypertension and organ damage
induced either by AT2 or aldosterone [32].
Despite large amounts of data from experimental studies
indicating the immunological basis of the pathogenesis of PH,
there are relatively few reports from clinical studies involving
children. Chronic sub-clinical inflammation is associated with
visceral obesity, is a predictor of the development of IR and
diabetes, and is considered to be a part of MS [33, 34]. A
cross-sectional analysis of data obtained from children aged
8–17 years in NHANES, between 1999 and 2004, revealed
that children with C-reactive protein levels above 3 mg/dl had
higher systolic blood pressure than children with C-reactive
protein levels below 3 mg/dl. Interestingly, that association
was observed solely in boys [35]. We also found that children
with PH had greater serum concentrations of highly sensitive
C-reactive protein (hsCRP) and chemokines (RANTES,
MIP1β), in comparison with normotensive children. The
hsCRP levels correlated with MS, visceral obesity, SOX and
markers of TOD, including increased carotid intima-media
thickness (cIMT) and LVMI [36].
Interaction of the renin–angiotensin system (RAS) with
peripheral blood leucocytes (PBL) provides another link be-
tween arterial hypertension and the immune system. RAS is
active in PBL and AT2, with ARBs affecting both innate and
adaptive immune systems [37–39]. In a study of gene expres-
sion in PBL in hypertensive adults, it was found that in un-
treated patients, the expression of 314 genes was up-regulated
(including those involved in inflammatory reactions, antioxi-
dative defense, and RAS) and 366 genes were down-regulat-
ed. Treatment led to a significant decrease of BP along with
almost full normalization of the pattern of gene expression
[40]. In another study in hypertensive adults, it was found that
PBL provided up-regulated expression of 21 genes known to
be engaged in apoptosis and inflammatory responses [41].
The interactions of the local RAS system and the immune
system occur early in the course of PH; this was found in a
study of children with PH observed before and after 6 months
of non-pharmacological treatment. PBL from untreated chil-
dren showed an increased expression of mRNA of the
angiotensin-converting enzyme and CD14 genes, while the
expression of angiotensinogen and AT2 type 1 receptor
mRNAs were down regulated. It was also found that children
with increased cIMT had a significantly lower renin gene
mRNA expression [42]. There is also data indicating that psy-
chosocial stress induces vascular dysfunction and hyperten-
sion through inflammatory mechanisms via nuclear factor
kappa B which is a proinflammatory transcription factor
(reviewed in [43]). It was also found that psychosocial stress
mediated by beta-adrenergic receptors caused nuclear factor
kappa B activation in PBL [44].
It has recently been reported that accelerated aging of the
immune system may play a role in the pathogenesis of hyper-
tensive arteriolosclerosis in the kidneys. It was found that
adults with PH had a higher number of circulating lympho-
cytes with markers of aging CD57+/CD8+ and CD28-/CD8+
when compared to normotensive controls [45]. Our prelimi-
nary data indicate that untreated adolescents with PH had sig-
nificantly more memory CD8+ T-cells than their normotensive
peers; this indirectly indicates accelerated aging of the im-
mune system (Fig. 1).
Dysregulation of the autonomic nervous system (ANS)
in children with PH
Several mechanisms leading to and maintaining central sym-
pathetic hyperactivity in PH have been identified. Impaired
vagal heart rate control exerted by an arterial baroreflex, im-
paired volume-sensitive cardiopulmonary reflex and arterial
chemoreceptors, as well as humoral factors such as AT2, al-
dosterone or leptin with direct central sympatho-excitatory
effects, have all been shown to play at least a partial role in
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hypertension (reviewed in [46]). The first reports were based
on observations of elevated heart rate and cardiac output in
children with elevated BP; such a hemodynamic pattern ful-
filled the criteria of hyperkinetic circulation. Hemodynamic
measurements in 95 adolescents, who were referred due to
PH, revealed that there was a significant increase in the cardi-
ac index from the normotensive/WCH phase, through the pre-
hypertension to ambulatory and severe ambulatory hyperten-
sion phase. However, the total peripheral resistance index de-
creased non-significantly; this helps explain the hemodynamic
mechanism in the elevation of BP [47]. In the Tecumseh
Study, Julius et al. found that a child who had a faster heart
rate at 7 years of age, also had higher BP values from the age
of 15 to 23. Moreover, that study proved that there is a Btwo-
way street^ between obesity and PH. Children who had higher
BP values at the age of 7 had a greater fat mass at the age of
22 years [48].
The relationship between obesity and increased sympathet-
ic drive is dependent on intact pathways of signal transmission
in the central nervous system, including leptin and
proopiomelanocortin pathways. Obese subjects who have a
mutated melanocortin receptor 4 do not present with an ele-
vated heart rate or PH despite their severe obesity [49]. Studies
of obese adults have shown that sympathetic drive measured
as muscle sympathetic nerve activity (MSNA), correlates with
WC. Moreover, it was found that sympathetic activation and
BP elevation associated with visceral obesity depend on an-
drogen action and are more exaggerated in boys than girls
[50]. There are currently no data directly comparing the
ANS activity of adolescent girls and boys, but the physiolog-
ical rise in BP is observed only in boys during their pubertal
growth spurt [51]. This corresponds with the dominance of
boys among adolescents with PH and the ratio of boys to girls
among adolescents with primary hypertension within our
studies; the ratio is 3–4:1.
Another indirect method of assessment of ANS function is
the analysis of cardiovascular rhythmicity. It was found that
children with both WCH and PH had significantly more prev-
alent ultradian (12-h) cardiovascular rhythms, with reduced
amplitudes and delayed acrophases in comparison to normo-
tensive children [52]. Interestingly, a repeated analysis per-
formed in PH patients after 12 months of treatment revealed
that the abnormal pattern of cardiovascular rhythms persisted
despite BP lowering. The normalization of acrophases and
diurnal cardiovascular rhythms was not determined by a BP
decrease, but rather by a decrease in the amount of visceral fat
assessed by WC and magnetic nuclear imaging [53]. These
findings suggest that sympathetic overactivity is indeed the
primary disturbance in hypertensive children.
Target organ damage and its association with metabolic
and immune abnormalities
There is a continuous proportional increase of LVMI, cIMT,
and arterial stiffness, related to the change in BP levels from
normotension through pre-hypertension, finally to sustained
hypertension [54]. In a recent meta-analysis on the relation-
ships between BP (assessed by ambulatory BP monitoring)
Fig. 1 Two isoforms of common leukocyte antigen (CD45), namely
CD45RO and CD45RA are expressed on Bmemory^ and naive T cells,
respectively [102]. The greater number of CD45RO-positive T cells, the
greater number of memory cells. Increase in CD45RO may result from
Bnaive^ T cell activation by as yet unknown endogenous stimuli so the
cells of the naive phenotype may acquire the memory phenotype (transi-
tion of RA into RO). Preliminary unpublished data: percentage of
CD45RO-positive CD8 T cells (upper panel) and ratio of 45RA to
45RO bearing CD8 T cells (lower panel) in 32 normotensive, healthy
adolescents vs. 72 hypertensive adolescents (both p<0.05)
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and TOD, it was found that hypertensive children had an
LVMI value greater by 6.9 g/height2.7 in comparison to nor-
motensive children [55]. Interestingly, children with WCH
had an LVMI greater by 2.9 g/height2.7 in comparison to nor-
motensive children [56, 57]. Hypertensive cardiac and arterial
injury was found in 40 % of adolescents with PH during di-
agnosis, along with the presence of severe LVH in 13–15 %
[58, 59]. Contrary to common belief, the most important de-
terminant of LVH in children with PH is not BP, but rather
BMI and metabolic abnormalities typical of MS. In fact, se-
vere LVH was found solely in hypertensive adolescents who
fulfilled all diagnostic criteria of MS [10]. Accordingly, Brady
et al. found that BP values were relatively weak determinants
of LVMI [59]. Moreover, it became apparent that the main
predictor of a decreasing LVMI during antihypertensive treat-
ment was not a decrease in BP, but rather a decrease of WC.
Similarly, the decrease of cIMT has been associated with the
decrease of WC and the normalization of inflammatory activ-
ity [19].
Early aging of the cardiovascular, metabolic, immune
and sympathetic system in children with PH
The above-described abnormalities associated with PH in
children and adolescents, such as accelerated tempo of
growth, visceral obesity with disturbed relationships between
fat and muscle mass, metabolic abnormalities, increased IMT,
stiffness of the arterial tree and immune alterations, are also
typical markers of accelerated or premature aging [60]. These
abnormalities also fit with the hypothesis of early vascular
aging (EVA) as an underlying phenomenon leading to clini-
cally overt cardiovascular disease [61]. Data from the Amster-
dam Growth and Health Longitudinal Study, indicate that,
individuals with stiffer carotid arteries at the age of 36 years
were characterized by ages 13 to 36 years, by higher BP and
steeper increases in WC, independently of each other and
other risk factors. Importantly, those increases were already
present in adolescence and preceded the development of dys-
lipidemia, a decrease of cardiorespiratory fitness and an in-
crease in heart rate [62].
Recently, more comprehensive models of PH development
that take into consideration alterations in the immune system,
activation of the SNS and metabolic abnormalities, including
SOX, have been proposed [63–65]. Furthermore, these
models give a temporal perspective on the development of
PH and its complications through the decades of life, along
with a few distinct phases where different pathogenic events
play a role. In the early pre-clinical stage, different stimuli
send signals to the central nervous system, which initiates
increased SNS activity. These signals are of different origin,
and include effects of adipokines released from visceral fat,
the activation of RAS with direct effects of AT2 on brain
centers, metabolic abnormalities mediated by insulin and
reactive oxygen species (ROS) or chronic stress. The domi-
nant clinical manifestation in the next phase is increased sym-
pathetic activity. TOD associated with metabolic abnormali-
ties, SOX and hemodynamic injury to the arterial wall, are
reversible during the early stages of the disease. However,
with time (likely decades) and ongoing exposure to innate
immune responses, the inflammatory reaction in the ar-
terial walls of both large and small arterioles causes a
release of neo-antigens [63].
The presentation of neo-antigens in dendritic cells triggers
an adaptive immune response against the arterial walls with a
central role being played by T-cells. This leads to irreversible
changes in the arterial and arteriolar walls, including kidney
vessels. The end phase consists in widespread hypertensive
arterial and arteriolar remodeling, with the addition of in-
creased arterial stiffness and development of hypertensive kid-
ney injury. This late phase may correspond to sodium-
sensitive hypertension, which is seen in the late stages of
hypertensive disease.
Neo-antigens are formed by intracellular proteins; there is
data indicating that neo-antigens are heat shock proteins
(HSP), which are very immunogenic in an extracellular envi-
ronment [66, 67]. The role of neo-antigens, and especially
HSP70 along with antibodies against HSPs, has been docu-
mented in experimental models of sodium-sensitive hyperten-
sion with inflammatory changes in the kidney [67]. Studies in
adults with borderline PH partially revealed elevated concen-
trations of HSP60 and anti-HSP65. However, in adults with
established hypertension and on average older by 18 years
than adults with borderline PH, antibodies against HSP70
and HSP65 were elevated, yet the levels of HSPs remained
the same as the control group [68, 69]. It should be mentioned
that in these studies, hypertensive patients presented with the
same intermediate phenotype of overweight/obesity, visceral
obesity, and insulin resistance, as was observed in the adoles-
cent patients with PH. There are no reports on HSPs or
other potential neo-antigens in children and adolescents
with PH; however, studies on early atherogenesis revealed
that the spectrum of elevated serum HSPs and reactivity
of T-lymphocytes against different HSPs is related to age
and advancement of disease. These studies showed a strict
relationship between reactivity against HSP60 and cIMT in
18-year-old adolescents and revealed that reactivity of
lymphocytes against HSP60 was the strongest determinant
of cIMT [70, 71].
Treatment of PH in childhood and adolescence: is
rejuvenation of the arterial system possible?
Due to the fact that all main alterations in PH resemble those
found in premature aging, one may say that the treatment
should focus on rejuvenation of the vascular system. It was
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found that immunosuppressive treatment directed against T-
lymphocytes, or applying mycophenolate mofetil, were both
effective in animal models of hypertension [72]. It was also
found that patients with rheumatoid arthritis treated with my-
cophenolate mofetil, had a lower prevalence of arterial hyper-
tension when compared to other patients [73]. However, due
to important severe side effects, immunosuppressive treatment
in the form of immunosuppressive drugs does not seem to be a
practical solution for the treatment of PH. There were several
attempts to use antioxidants as a solitary or supplementary
therapy in adults with PH, but the results of those trials have
remained disappointing [74]. Thus, there remain two main
forms of antihypertensive treatment; non-pharmacological
and pharmacological therapy.
Non-pharmacological treatment is based on daily physical
activity and diet. According to the guidelines, it is recom-
mended to start pharmacological treatment in all cases of
life-threatening and secondary hypertension. In cases of PH
in children, pharmacological treatment should commence
with TOD and/or with stage 2 hypertension or when non-
pharmacological treatment is ineffective. Most children and
adolescents with PH present with stage 1 hypertension with
only subtle TOD and should therefore begin non-
pharmacological therapy. The efficiency of non-
pharmacological treatment based on vigorous physical exer-
cise and diet depends on the motivation and conscious deci-
sions made by the patient in reference to make a change to his/
her lifestyle. The effects are quite small in adults but quite
encouraging in children and adolescents. The treatment
should be focused towards decreasing visceral fat and increas-
ing fitness level; physical exercise exerts significant positive
effects, which act at a molecular level on the main distur-
bances found in PH [75]. Preventive and therapeutic effects
of structured exercise training during adulthood, is well doc-
umented [76]. Importantly, physical fitness exerts a strong
modifying effect on BP trajectories over the life span of an
adult male. Results from the Aerobics Centre Longitudinal
Study, including 13,953 men between 20 and 90 years of
age without hypertension, cardiovascular disease or cancer,
who completed 3 to 28 (mean of 3.8) follow-up medical ex-
aminations between 1970 and 2006, showed that subjects with
higher fitness levels experienced an SBP increase later than
those with low fitness levels [77]. Interventional studies in
children showed that physical activity is associated with the
lowering of BP in 11–12-year-old obese and hypertensive
children. It was also found that volume is more important than
intensity when referring to physical activity [78]. In one of the
first reports on the effects of non-pharmacological therapies
on obese children, it was found that both exercise and diet
caused significant hypotensive effects and increased post-
ischemic dilation of the forearm vessels. However, the effects
of exercise programs were significantly greater in terms of BP
reduction, improvement in cardiovascular fitness and
endothelial function when compared to diet alone [79]. Sim-
ilarly, Woo et al. documented that diet plus exercise caused
greater positive effects on endothelial function in 9–12-year-
old obese children when compared to diet alone. Significant
improvement of flow-mediated dilation in the brachial artery
was evident after only 6 weeks, with sustained improvement
being observed in those who exercised regularly for 1 year
[80].
When deciding on pharmacological treatment, one may
choose from eight different groups of antihypertensive medi-
cations. However, some of these medications may also cause
more harm than benefit when used in adolescents with PH;
this is not considered BP lowering, but rather a decrease in
cardiovascular risk.
Thiazides are the most commonly prescribed antihyperten-
sive drugs worldwide; however, their use poses the risk of DM
and worsening of metabolic abnormalities [81]. A recent
meta-analysis of 22 clinical trials with 143,153 non-DM pa-
tients revealed that antihypertensive treatment, with a combi-
nation of diuretics, was associated with an increased risk of
new-onset DM when compared to other antihypertensive
agents or placebo [82]. Also, the ALLHAT study showed that
chlorthalidone produced a greater increase in the fasting glu-
cose level and a significantly higher risk of DM than that of
amlodipine or lisinopril [83]. Therefore, thiazides and other
diuretics should not be used as the first or even second-line
drug of choice, regarding the treatment of PH in children and
adolescents.
Although beta-blockers slow down the heart rate and de-
crease BP, their primary use is associated with the develop-
ment of obesity and IR [84]. Weight gain during beta-blocker
therapy is mainly related to reduced energy expenditure.
Sharma et al. showed that beta-blockers in obese hypertensive
patients reduced the basal metabolic rate by 12 % when com-
pared with other antihypertensive therapies [85]. Furthermore,
beta-blockers decreased insulin secretion from pancreatic β-
cells along with blood flow in the skeletal muscles, which led
to the impairment of glucose metabolism and IR. A large
meta-analysis of hypertensive patients treated with beta-
blockers revealed an increased risk of new-onset DM com-
pared to other non-diuretic antihypertensive agents [86]. How-
ever, it seems that there are significant differences throughout
the spectrum of adverse metabolic effects caused by non-
selective and selective beta-blockers. It was found that a
long-acting form of metoprolol, which is a selective beta1-
blocker, did not aggravate insulin resistance [87, 88]. Never-
theless, the direct comparison of nebivolol and metoprolol
indicated that nebivolol had a better metabolic profile as it
did not increase IR or SOX [89, 90]. In view of these poten-
tially severe adverse effects, beta-blockade should not be used
as first-line therapy in children and adolescents. However,
new beta-blockers such as nebivolol, are devoid of the nega-
tive effects of old beta-blockers and may be an alternative for
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adolescent girls with PH, in whom the use of blockers of the
RAS system can be problematic due to the adverse effects of
RAS blockers in pregnancy.
From a pathophysiological point of view, the best choices
in pharmacological therapy of PH are drugs which exert not
only hypotensive effects, but also positive metabolic effects.
The best choices are dihydropyridine calcium channel
blockers (CCBs) which are metabolically neutral and blockers
of the renin–angiotensin system – ACE inhibitors (ACEi) and
AT2 receptor blockers (ARBs).
CCBs are generally considered as having a low potential to
impair the metabolic profile. Indeed, a meta-analysis of ten
randomized clinical trials evaluated the effects of antihyper-
tensive drugs on glucose metabolism. It was found that the
risk of new-onset DM among subjects taking CCBs was not
significantly greater compared to patients treated with beta-
blockers or diuretics. However, CCBs were associated with a
higher incidence of DM than ACEi [91]. On the other hand, a
recent re-analysis of data from the NAVIGATOR trial showed
that CCBs were not associated with a higher risk of new-onset
DM [92].
The majority of clinical trials evaluating the effects of
ACEi and ARBs on glucose homeostasis have revealed that
inhibition of the RAS system was associated with increased
insulin sensitivity, better glucose uptake by the skeletal mus-
cles and a lower incidence of new-onset DM in hypertensive
subjects. The HOPE study demonstrated a favorable influence
of ramipril on cardiovascular incidents in high-risk patients
and a reduction of new-onset DM by 34 % when compared
to placebo [93]. The ALLHAT trial, which evaluated the in-
fluence of CCBs, ACEi and diuretics on cardiovascular
events, revealed that lisinopril reduced the relative risk of de-
veloping DM by 30 % when compared to chlorthalidone and
by 17 % when compared to amlodipine therapy [83]. In addi-
tion, the LIFE study, which enrolled 9,193 patients treated
with atenolol or losartan, showed a significantly reduced
new-onset DM in the losartan group compared to the atenolol
group [94]. Similar results have also been presented in other
studies [95, 96]. Some findings have indicated that weight loss
in obese individuals was associated with the inhibition of RAS
[97]. This may be partly due to reduced SNS activity, resulting
in decreased renin release and change in adipocyte function.
The inhibition of RAS may result in a shift in adipocyte dis-
tribution from visceral to subcutaneous depots. Furthermore,
there is a correlation between 24-h BP and the expression of
genes related to RAS in adipocytes [98, 99].Moreover, it has
been suggested that AT2 increases SOX in human pre-
adipocytes and can be inhibited by ARB. Telmisartan was
more effective in this field than other ARBs. It was found that
telmisartan improved adiponectin secretion in pre-adipocytes
and had beneficial metabolic effects via selective peroxisome
proliferator-activated receptor-γ modulation [100]. In addi-
tion, patients treated with ACEi or ARBs showed a significant
reduction in visceral fat, compared to other antihypertensive
drugs. In a study involving 54 Japanese patients with MS and
abdominal obesity, telmisartan was associated with a signifi-
cant reduction in the plasma glucose/insulin levels and viscer-
al fat tissue, whereas amlodipine had no effect [101].
Conclusions
We have concluded that primary hypertension in children and
adolescents is not a purely hemodynamic phenomenon, but
rather an immune-metabolic syndrome associated with an in-
creased sympathetic drive. The main intermediate phenotypes
of PH in children resemble those observed during normal
aging. The best initial treatment of PH is the combination of
non-pharmacological therapy based on physical exercise and
diet. In some patients, additional use of antihypertensive med-
ications, ideally blockers of RAS are needed. These can lead
to rejuvenation of the vascular system and improvement of
metabolic abnormalities.
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